The efficacy and safety of ketamine for depression in patients with cancer: A systematic review

IF 5.3 1区心理学 Q1 PSYCHOLOGY, CLINICAL

International Journal of Clinical and Health Psychology Pub Date : 2023-12-15 DOI:10.1016/j.ijchp.2023.100428

Leila Azari , Homa Hemati , Ronia Tavasolian , Sareh Shahdab , Stephanie M. Tomlinson , Margarita Bobonis Babilonia , Jeffrey Huang , Danielle B. Tometich , Kea Turner , Heather S.L. Jim , Amir Alishahi Tabriz

{"title":"The efficacy and safety of ketamine for depression in patients with cancer: A systematic review","authors":"Leila Azari , Homa Hemati , Ronia Tavasolian , Sareh Shahdab , Stephanie M. Tomlinson , Margarita Bobonis Babilonia , Jeffrey Huang , Danielle B. Tometich , Kea Turner , Heather S.L. Jim , Amir Alishahi Tabriz","doi":"10.1016/j.ijchp.2023.100428","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Management of depression in the oncology population includes supportive psychotherapeutic interventions with or without psychotropic medication, which take time to demonstrate effectiveness. Fast-acting interventions, like ketamine, can provide a rapid antidepressant effect; however, there has been limited research on effects of ketamine among cancer patients. The objective of this review is to provide an overview of research on the efficacy and safety of ketamine on depression in patients with cancer.</p></div><div><h3>Methods</h3><p>We reviewed the published literature in MEDLINE® (via PubMed®), EMBASE, and Scopus from 1 January 1982 to 20 October 2022. We screened the retrieved abstracts against inclusion criteria and conducted a full‐text review of eligible studies. Following extraction of data from included studies, we used a framework analysis approach to summarize the evidence on using ketamine in patients with cancer.</p></div><div><h3>Results</h3><p>All 5 included studies were randomized clinical trials conducted in inpatient settings in China. In all included studies ketamine was administered intravenously. Three studies used only racemic ketamine, and two studies used both S-ketamine and racemic ketamine. All included studies reported ketamine a tolerable and effective drug to control depression symptoms.</p></div><div><h3>Conclusion</h3><p>Included studies showed administration of sub-anesthesia ketamine significantly improves postoperative depression among patients with cancer.</p></div>","PeriodicalId":47673,"journal":{"name":"International Journal of Clinical and Health Psychology","volume":"24 1","pages":"Article 100428"},"PeriodicalIF":5.3000,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1697260023000649/pdfft?md5=7e35195763b03243e7ff32b64c9c5e8d&pid=1-s2.0-S1697260023000649-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical and Health Psychology","FirstCategoryId":"102","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1697260023000649","RegionNum":1,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Management of depression in the oncology population includes supportive psychotherapeutic interventions with or without psychotropic medication, which take time to demonstrate effectiveness. Fast-acting interventions, like ketamine, can provide a rapid antidepressant effect; however, there has been limited research on effects of ketamine among cancer patients. The objective of this review is to provide an overview of research on the efficacy and safety of ketamine on depression in patients with cancer.

Methods

We reviewed the published literature in MEDLINE® (via PubMed®), EMBASE, and Scopus from 1 January 1982 to 20 October 2022. We screened the retrieved abstracts against inclusion criteria and conducted a full‐text review of eligible studies. Following extraction of data from included studies, we used a framework analysis approach to summarize the evidence on using ketamine in patients with cancer.

Results

All 5 included studies were randomized clinical trials conducted in inpatient settings in China. In all included studies ketamine was administered intravenously. Three studies used only racemic ketamine, and two studies used both S-ketamine and racemic ketamine. All included studies reported ketamine a tolerable and effective drug to control depression symptoms.

Conclusion

Included studies showed administration of sub-anesthesia ketamine significantly improves postoperative depression among patients with cancer.

查看原文本刊更多论文

氯胺酮治疗癌症患者抑郁症的有效性和安全性：系统综述

背景肿瘤患者抑郁症的治疗包括支持性心理治疗干预，无论是否使用精神药物，这些干预都需要时间才能显现效果。氯胺酮等速效干预措施可迅速产生抗抑郁效果；然而，有关氯胺酮在癌症患者中效果的研究却很有限。本综述旨在概述氯胺酮对癌症患者抑郁症的疗效和安全性的研究。方法我们查阅了从 1982 年 1 月 1 日至 2022 年 10 月 20 日在 MEDLINE®（通过 PubMed®）、EMBASE 和 Scopus 上发表的文献。我们根据纳入标准筛选了检索到的摘要，并对符合条件的研究进行了全文综述。从纳入的研究中提取数据后，我们采用框架分析法总结了在癌症患者中使用氯胺酮的证据。在所有纳入的研究中，氯胺酮均为静脉给药。三项研究仅使用外消旋氯胺酮，两项研究同时使用S-氯胺酮和外消旋氯胺酮。结论纳入的研究表明，麻醉下使用氯胺酮可显著改善癌症患者的术后抑郁。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Clinical and Health Psychology PSYCHOLOGY, CLINICAL-

CiteScore

10.70

自引率

5.70%

发文量

审稿时长

33 days

期刊介绍： The International Journal of Clinical and Health Psychology is dedicated to publishing manuscripts with a strong emphasis on both basic and applied research, encompassing experimental, clinical, and theoretical contributions that advance the fields of Clinical and Health Psychology. With a focus on four core domains—clinical psychology and psychotherapy, psychopathology, health psychology, and clinical neurosciences—the IJCHP seeks to provide a comprehensive platform for scholarly discourse and innovation. The journal accepts Original Articles (empirical studies) and Review Articles. Manuscripts submitted to IJCHP should be original and not previously published or under consideration elsewhere. All signing authors must unanimously agree on the submitted version of the manuscript. By submitting their work, authors agree to transfer their copyrights to the Journal for the duration of the editorial process.